Phospholipase Cδ-4 (PLCδ4) Acts As a Nuclear Player to Influence Cyclin B Expression in the Embryonal Rhabdomyosarcoma Cell Lines RD and A204

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Sep 28

PMID 39334946

Authors

Sara Salucci

Alberto Bavelloni

Ilaria Versari

Sabrina Burattini

Francesco Bavelloni

Pietro Gobbi

Alessandro Fanzani

Silvia Codenotti

William Blalock

Katia Scotlandi

Irene Faenza

Affiliations

Soon will be listed here.

Abstract

Rhabdomyosarcoma (RMS), the most common form of sarcoma typical of pediatric age, arises from the malignant transformation of the mesenchymal precursors that fail to differentiate into skeletal muscle cells. Here, we investigated whether the protein phospholipase C δ4 (PLCδ4), a member of the PLC family involved in proliferation and senescence mechanisms of mesenchymal stromal stem cells, may play a role in RMS. Our molecular and morpho-functional data reveal that PLCδ4 is highly expressed in the fusion-negative, p53-positive, SMARCB1 heterozygous mutated embryonal RMS (ERMS) cell line A204, while it is poorly expressed in the ERMS cell lines RD (fusion-negative, MYC amplification, N-RAS (Q61H), homozygous mutated p53) and Hs729 (homozygous mutated p53) and the alveolar rhabdosarcoma (ARMS) cell line SJCRH30 (RH30; fusion positive, heterozygous mutated RARA, polyheterozygous mutated p53). To characterize the role of PLCδ4, the RD cell line was stably transfected with wild-type PLCδ4 (RD/PLCδ4). Overexpressed PLCδ4 mainly localized to the nucleus in RD cells and contributed to the phosphorylation of PRAS40 (T246), Chk2(T68), WNK1(T60), and Akt 1/273 (S473), as revealed by proteome profiler array analysis. Overexpression of PLCδ4 in RD cells enhanced cyclin B1 expression and resulted in G2/M-phase cell cycle arrest. In contrast, siRNA-mediated knockdown of PLCδ4 in A204 cells resulted in reduced cyclin B1 expression. Our study identifies a novel role for nuclear PLCδ4 as a regulator of cyclin B1 via Akt-dependent phosphorylation. The modulation of PLCδ4 expression and its downstream targets could represent a crucial signaling pathway to block embryonal RMS cell proliferation.

References

Burattini S, Battistelli M, Codenotti S, Falcieri E, Fanzani A, Salucci S . Melatonin action in tumor skeletal muscle cells: an ultrastructural study. Acta Histochem. 2016; 118(3):278-85. DOI: 10.1016/j.acthis.2016.02.004. View

Lee Y, Shin K, Jang H, Noh D, Ryu S, Suh P . Phospholipase Signaling in Breast Cancer. Adv Exp Med Biol. 2021; 1187:23-52. DOI: 10.1007/978-981-32-9620-6_2. View

Castano E, Yildirim S, Faberova V, Krausova A, Ulicna L, Paprckova D . Nuclear Phosphoinositides-Versatile Regulators of Genome Functions. Cells. 2019; 8(7). PMC: 6678639. DOI: 10.3390/cells8070649. View

Poduri A, Chopra S, Neilan E, Elhosary P, Kurian M, Meyer E . Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 2012; 53(8):e146-50. PMC: 3851296. DOI: 10.1111/j.1528-1167.2012.03538.x. View

Wiza C, Nascimento E, Ouwens D . Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab. 2012; 302(12):E1453-60. DOI: 10.1152/ajpendo.00660.2011. View

Kunrath-Lima M, de Miranda M, da Fonseca Ferreira A, Fraga Faraco C, Melo M, Goes A . Phospholipase C delta 4 (PLCδ4) is a nuclear protein involved in cell proliferation and senescence in mesenchymal stromal stem cells. Cell Signal. 2018; 49:59-67. PMC: 6095203. DOI: 10.1016/j.cellsig.2018.05.011. View

Liu N, Fukami K, Yu H, Takenawa T . A new phospholipase C delta 4 is induced at S-phase of the cell cycle and appears in the nucleus. J Biol Chem. 1996; 271(1):355-60. DOI: 10.1074/jbc.271.1.355. View

Ibrahim N . Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer. Front Oncol. 2021; 11:617874. PMC: 8290913. DOI: 10.3389/fonc.2021.617874. View

Piazzi M, Bavelloni A, Cenni V, Salucci S, Stella A, Tomassini E . Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells. Molecules. 2022; 27(9). PMC: 9104989. DOI: 10.3390/molecules27092742. View

10.

Lien E, Dibble C, Toker A . PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017; 45:62-71. PMC: 5482768. DOI: 10.1016/j.ceb.2017.02.007. View

11.

Liang S, Guo H, Ma K, Li X, Wu D, Wang Y . A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression. Cancer Res. 2021; 81(23):5889-5903. PMC: 9397629. DOI: 10.1158/0008-5472.CAN-21-1538. View

12.

Faenza I, Matteucci A, Manzoli L, Billi A, Aluigi M, Peruzzi D . A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem. 2000; 275(39):30520-4. DOI: 10.1074/jbc.M004630200. View

13.

Naeem A, Zhu Y, Di W, Marmiroli S, OShaughnessy R . AKT1-mediated Lamin A/C degradation is required for nuclear degradation and normal epidermal terminal differentiation. Cell Death Differ. 2015; 22(12):2123-32. PMC: 4816115. DOI: 10.1038/cdd.2015.62. View

14.

Leung D, Tompkins C, Brewer J, Ball A, Coon M, Morris V . Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells. Mol Cancer. 2004; 3:15. PMC: 420486. DOI: 10.1186/1476-4598-3-15. View

15.

Khalatbari H, Shulkin B, Parisi M . PET/CT and PET/MR in Soft Tissue Sarcoma: An Update. Semin Nucl Med. 2024; 54(3):313-331. DOI: 10.1053/j.semnuclmed.2024.01.005. View

16.

Salucci S, Bavelloni A, Stella A, Fabbri F, Vannini I, Piazzi M . The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling. Nutrients. 2023; 15(3). PMC: 9920154. DOI: 10.3390/nu15030740. View

17.

Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H . Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010; 70(16):6566-76. PMC: 2922473. DOI: 10.1158/0008-5472.CAN-10-0942. View

18.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

19.

Tian Z, Yao W . Chemotherapeutic drugs for soft tissue sarcomas: a review. Front Pharmacol. 2023; 14:1199292. PMC: 10450752. DOI: 10.3389/fphar.2023.1199292. View

20.

Marmiroli S, Bertacchini J, Beretti F, Cenni V, Guida M, de Pol A . A-type lamins and signaling: the PI 3-kinase/Akt pathway moves forward. J Cell Physiol. 2009; 220(3):553-61. DOI: 10.1002/jcp.21807. View